OS Therapies releases trial data supporting FDA approval, U.K. and U.S. timelines, and potential eligibility for a valuable ...
SurvivorNet on MSN
Cancer patients are living longer — a closer look at the treatments driving this progress
New data show cancer survival has reached a record high — nearly 70% of patients now live at least five years after diagnosis ...
Inhibrx Biosciences, Inc. stays a Strong Buy with Q2 2026 ozekibart BLA catalyst, 2026 PFS data, and Ewing sarcoma updates.
The patient with significant bone marrow involvement had complete bone morphological remission. In this patient in which 95% ...
News-Medical.Net on MSN
Study tests combined targeted radiopharmaceuticals and precision radiation for recurrent prostate cancer
Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have opened a clinical trial that will look at whether ...
A team of Australian researchers has developed a novel targeted therapeutic approach that could significantly advance the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback